Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01255917 · ClinicalTrials.gov registry record
Nerve Growth Factor in Chronic Pancreatitis
A clinical trial, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- 38
- Enrollment target
NCT01255917: Completed study, sponsored by Virginia Commonwealth University.
NCT01255917 is a clinical trial that has completed, run by Virginia Commonwealth University. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01255917 has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
Study Summary
This study is to understand the role of nerve growth factor(NGF) and other cytokines in the pancreatic fluid of patients with chronic pancreatitis. Hypothesis: 1. Pain does not correlate with changes in the PD morphology suggesting that pain in CP is not only a mechanical problem 2. Pain in CP correlates better with the levels of NGF in the pancreatic juice. NGF is variably expressed in different morphological stages of CP and regulates the sensitivity of the peptidergic nociceptors and is upregulated in pancreatic inflammation.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2008-02 |
| Est. Completion | 2011-08 |
What the finished NCT01255917 record still lists
NCT01255917 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01255917 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01255917 about?
NCT01255917 is a clinical study titled "Nerve Growth Factor in Chronic Pancreatitis". This study is to understand the role of nerve growth factor(NGF) and other cytokines in the pancreatic fluid of patients with chronic pancreatitis. Hypothesis: 1. Pain does not correlate with changes in the PD morphology suggesting that pain in CP is not only a mechanical problem 2. Pain in CP cor...
What is the current status of trial NCT01255917?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2008-02. Estimated completion is 2011-08.
Who is sponsoring clinical trial NCT01255917?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia